732 related articles for article (PubMed ID: 14623544)
21. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
22. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
23. Intracrine mechanism of estrogen synthesis in breast cancer.
Suzuki T; Moriya T; Ishida T; Ohuchi N; Sasano H
Biomed Pharmacother; 2003 Dec; 57(10):460-2. PubMed ID: 14637389
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo.
Ishida H; Nakata T; Sato N; Li PK; Kuwabara T; Akinaga S
Breast Cancer Res Treat; 2007 Aug; 104(2):211-9. PubMed ID: 17061037
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives.
Selcer KW; Jagannathan S; Rhodes ME; Li PK
J Steroid Biochem Mol Biol; 1996 Sep; 59(1):83-91. PubMed ID: 9009241
[TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitors and their antitumor effects in model systems.
Brodie A; Lu Q; Liu Y; Long B
Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
[TBL] [Abstract][Full Text] [Related]
27. Steroid sulfatase: molecular biology, regulation, and inhibition.
Reed MJ; Purohit A; Woo LW; Newman SP; Potter BV
Endocr Rev; 2005 Apr; 26(2):171-202. PubMed ID: 15561802
[TBL] [Abstract][Full Text] [Related]
28. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
29. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Pasqualini JR; Chetrite G; Blacker C; Feinstein MC; Delalonde L; Talbi M; Maloche C
J Clin Endocrinol Metab; 1996 Apr; 81(4):1460-4. PubMed ID: 8636351
[TBL] [Abstract][Full Text] [Related]
30. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.
Pasqualini JR; Cortes-Prieto J; Chetrite G; Talbi M; Ruiz A
Int J Cancer; 1997 Mar; 70(6):639-43. PubMed ID: 9096642
[TBL] [Abstract][Full Text] [Related]
31. Steroid sulfatase inhibitors: their potential in the therapy of breast cancer.
Nussbaumer P; Billich A
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):507-28. PubMed ID: 16178776
[TBL] [Abstract][Full Text] [Related]
32. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo.
James MR; Skaar TC; Lee RY; MacPherson A; Zwiebel JA; Ahluwalia BS; Ampy F; Clarke R
Endocrinology; 2001 Apr; 142(4):1497-505. PubMed ID: 11250930
[TBL] [Abstract][Full Text] [Related]
33. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures.
Santner SJ; Ohlsson-Wilhelm B; Santen RJ
Int J Cancer; 1993 Apr; 54(1):119-24. PubMed ID: 8478138
[TBL] [Abstract][Full Text] [Related]
34. Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
Ahmed S; Owen CP; James K; Sampson L; Patel CK
Curr Med Chem; 2002 Jan; 9(2):263-73. PubMed ID: 11860358
[TBL] [Abstract][Full Text] [Related]
35. The selective estrogen enzyme modulators in breast cancer: a review.
Pasqualini JR
Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; Dobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC
Clin Cancer Res; 2006 Mar; 12(5):1585-92. PubMed ID: 16533785
[TBL] [Abstract][Full Text] [Related]
37. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
Foster PA; Newman SP; Chander SK; Stengel C; Jhalli R; Woo LL; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2006 Sep; 12(18):5543-9. PubMed ID: 17000691
[TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
39. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
40. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
Santner SJ; Feil PD; Santen RJ
J Clin Endocrinol Metab; 1984 Jul; 59(1):29-33. PubMed ID: 6725522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
